Last reviewed · How we verify
IPX203 ER CD-LD
IPX203 ER CD-LD is a combination extended-release formulation of carbidopa and levodopa designed to provide sustained dopaminergic replacement therapy for Parkinson's disease with reduced dosing frequency.
IPX203 ER CD-LD is a combination extended-release formulation of carbidopa and levodopa designed to provide sustained dopaminergic replacement therapy for Parkinson's disease with reduced dosing frequency. Used for Parkinson's disease motor symptoms.
At a glance
| Generic name | IPX203 ER CD-LD |
|---|---|
| Sponsor | Impax Laboratories, LLC |
| Drug class | Dopaminergic agent; levodopa/carbidopa combination |
| Target | Dopamine pathway; aromatic L-amino acid decarboxylase inhibition |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels in Parkinson's disease, while carbidopa is a peripheral decarboxylase inhibitor that prevents premature conversion of levodopa in the periphery, allowing more drug to reach the central nervous system. The extended-release formulation with controlled delivery (CD) aims to maintain more stable plasma levels and reduce motor fluctuations compared to immediate-release formulations.
Approved indications
- Parkinson's disease motor symptoms
Common side effects
- Dyskinesia
- Motor fluctuations
- Nausea
- Dizziness
- Orthostatic hypotension
Key clinical trials
- A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease (PHASE4)
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations (PHASE3)
- A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease (PHASE2)
- A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPX203 ER CD-LD CI brief — competitive landscape report
- IPX203 ER CD-LD updates RSS · CI watch RSS
- Impax Laboratories, LLC portfolio CI